{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:23Z","timestamp":1791231443062,"version":"4.1.0"},"reference-count":87,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2015.00046","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T10:06:02Z","timestamp":1423476362000},"source":"Crossref","is-referenced-by-count":51,"title":["Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment"],"prefix":"10.3389","volume":"6","author":[{"given":"Mariana","family":"Aris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00c3\u00ada Marcela","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.6004\/jnccn.2013.0055","article-title":"Melanoma, version 2.2013: featured updates to the NCCN guidelines","volume":"11","author":"Coit","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"6736","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.clindermatol.2012.08.003","article-title":"Melanoma genetics: the other side","volume":"31","author":"Bis","year":"2013","journal-title":"Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Berger","year":"2012","journal-title":"Nature"},{"issue":"2","key":"B9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/jid.2014.366","article-title":"Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma","volume":"135","author":"Siroy","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma","volume":"15","author":"Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"B12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.1026","article-title":"Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma","volume":"44","author":"Nikolaev","year":"2012","journal-title":"Nat Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Klein","year":"2013","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1186\/1471-2407-14-727","article-title":"The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma","volume":"14","author":"Trudel","year":"2014","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.438.Analysis","article-title":"Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4","volume":"41","author":"Prickett","year":"2009","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/cncr.25766","article-title":"A phase 2 trial of dasatinib in advanced melanoma","volume":"117","author":"Kluger","year":"2011","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u00e2\u20ac\u2122s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"192719","DOI":"10.1155\/2012\/192719","article-title":"Lessons from cancer immunoediting in cutaneous melanoma","volume":"2012","author":"Aris","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"B29","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u00e2\u20ac\u201cPD-L1 antibody in patients with advanced cancer","volume":"366","author":"Hwu","year":"2012","journal-title":"N Engl J Med"},{"key":"B30","first-page":"39","article-title":"Cutaneous melanoma: molecular biology, risk factors and treatment options","volume-title":"Melanoma: Molecular Biology, Risk Factors and Treatment Options","author":"Aris"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.4049\/jimmunol.175.9.6169","article-title":"Tumor progression can occur despite the induction of very high levels of self\/tumor antigen-specific CD8+ T cells in patients with melanoma","volume":"175","author":"Rosenberg","year":"2005","journal-title":"J Immunol"},{"issue":"9","key":"B32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.4161\/onci.22428","article-title":"Peptide vaccines in cancer therapy trial watch","volume":"1","author":"Vacchelli","year":"2012","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e24743","DOI":"10.4161\/onci.24743","article-title":"Peptide-based anticancer vaccines: the making and unmaking of a T-cell graveyard","volume":"2","author":"Hailemichael","year":"2013","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/jid.2011.312","article-title":"MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro","volume":"132","author":"Aris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","article-title":"Antigens for cancer immunotherapy","volume":"20","author":"Neller","year":"2008","journal-title":"Semin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/14760584.4.3.259","article-title":"Vaccines in cancer: GVAX, a GM-CSF gene vaccine","volume":"4","author":"Nemunaitis","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.cji.0000208258.79005.5f","article-title":"A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients","volume":"29","author":"Barrio","year":"2006","journal-title":"J Immunother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1158\/1078-0432.CCR-10-3223","article-title":"Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer","volume":"17","author":"Beer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3892\/or.2012.1956","article-title":"Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial","volume":"28","author":"Oshita","year":"2012","journal-title":"Oncol Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/CJI.0b013e318159f5ba","article-title":"Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients","volume":"31","author":"Bercovici","year":"2008","journal-title":"J Immunother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/01.cji.0000211309.90621.8b","article-title":"Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity","volume":"29","author":"Palucka","year":"2006","journal-title":"J Immunother"},{"key":"B43","doi-asserted-by":"publisher","first-page":"976383","DOI":"10.1155\/2013\/976383","article-title":"Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)","volume":"2013","author":"Benteyn","year":"2013","journal-title":"Biomed Res Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.4049\/jimmunol.171.11.5940","article-title":"Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma","volume":"171","author":"Goldszmid","year":"2003","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1479-5876-5-19","article-title":"Monocyte-derived dendritic cells loaded with a mixture of apoptotic\/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes","volume":"5","author":"Von Euw","year":"2007","journal-title":"J Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1479-5876-6-6","article-title":"A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic\/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of diseas","volume":"6","author":"Von Euw","year":"2008","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","article-title":"Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients","volume":"16","author":"Besser","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1200\/JCO.2006.10.2822","article-title":"Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy","volume":"25","author":"Tarhini","year":"2007","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/jps.21596","article-title":"Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy","volume":"98","author":"Shaker","year":"2009","journal-title":"J Pharm Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"D479","DOI":"10.2741\/Sangfelt","article-title":"Mechanisms of interferon-induced cell cycle arrest","volume":"5","author":"Sangfelt","year":"2000","journal-title":"Front Biosci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2141.1994.tb05017.x","article-title":"Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo","volume":"88","author":"Jewell","year":"1994","journal-title":"Br J Haematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/MO:18:1:3","article-title":"Apoptosis and cell growth inhibition as antitumor effector functions of interferons","volume":"18","author":"Sangfelt","year":"2001","journal-title":"Med Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/ph3040994","article-title":"Antiproliferative properties of type I and type II interferon","volume":"3","author":"Bekisz","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2004.09.026","article-title":"Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis","volume":"6","author":"Tang","year":"2004","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/jir.2008.0118","article-title":"VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines","volume":"28","author":"Raig","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/intimm\/dxm058","article-title":"Involvement of oxidative and nitrosative stress in modulation of gene expression and functional responses by IFNgamma","volume":"19","author":"Prasanna","year":"2007","journal-title":"Int Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/CMR.0b013e32833e3286","article-title":"In-vitro IL-2 or IFN-\u00ce\u00b1-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients","volume":"20","author":"Konjevi\u00c4\u2021","year":"2010","journal-title":"Melanoma Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0959-8049(12)71706-9","article-title":"In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-\u00ce\u00b1 alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression","volume":"17","author":"Konjevic","year":"2012","journal-title":"J BUON"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e18801","DOI":"10.1371\/journal.pone.0018801","article-title":"Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis","volume":"6","author":"Draube","year":"2011","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00262-012-1207-7","article-title":"Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma","volume":"61","author":"Leonhartsberger","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B66","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jnci\/djr514","article-title":"Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer","volume":"104","author":"Huber","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B68","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1634\/theoncologist.2010-0129","article-title":"Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","volume":"15","author":"Madan","year":"2010","journal-title":"Oncologist"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1172\/JCI66236DS1","article-title":"Host immunity contributes to the anti- melanoma activity of BRAF inhibitors","volume":"123","author":"Knight","year":"2013","journal-title":"J Clin Invest"},{"issue":"24","key":"B72","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1158\/0008-5472.CAN-14-1339","article-title":"Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma","volume":"74","author":"De Andrade","year":"2014","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1158\/1078-0432.CCR-10-1911","article-title":"The oncogenic BRAF kinase inhibitor PLX4032\/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations","volume":"16","author":"Comin-Anduix","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-13-0160","article-title":"Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor","volume":"2","author":"Callahan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4161\/onci.19865","article-title":"Combined targeted therapy and immunotherapy in the treatment of advanced melanoma","volume":"1","author":"Wilmott","year":"2012","journal-title":"Oncoimmunology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMc1301264","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","article-title":"Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib","volume":"49","author":"Hantschel","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e28925","DOI":"10.4161\/onci.28925","article-title":"Dasatinib promotes Th1-type responses in granzyme B expressing T-cells","volume":"3","author":"Kreutzman","year":"2014","journal-title":"Oncoimmunology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e27589","DOI":"10.4161\/onci.27589","article-title":"Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma","volume":"3","author":"Lowe","year":"2014","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1182\/blood-2012-02-407163","article-title":"Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40","volume":"120","author":"Yang","year":"2012","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J Clin Invest"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e6910","DOI":"10.1371\/journal.pone.0006910","article-title":"The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase","volume":"4","author":"S\u00c3\u00b8rensen","year":"2009","journal-title":"PLoS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4161\/cbt.6.9.4569","article-title":"Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells","volume":"6","author":"Kumar","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T15:52:12Z","timestamp":1566316332000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fimmu.2015.00046\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,9]]},"references-count":87,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2015.00046","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,9]]}}}